ATTeST Trail

The ATTeST Trial of dexamethasone sodium phosphate delivered by the Erydex system, is the first ever multi-centre, phase 3 trial of a treatment for A-T. This double-blind placebo-controlled trial aims to evaluate the effectiveness of dexamethasone, delivered by a novel method of encapsulation in the patient’s own red blood cells, in treating the neurological effects of A-T.

The trial involves 180 patients in 23 centres on 5 different continents. The project has received funding from the Horizon 2020 grant which is funding this registry and it is therefore a requirement of the grant that all patients enrolled in the trial should be included in this registry.

More information on the study can be obtained from the trial website

The EryDex System

Logo of the ATTeST trial